User menu

Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.

Bibliographic reference Clavé, P ; Acalovschi, M ; Triantafillidis, J K ; Uspensky, Y P ; Kalayci, C ; et. al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.. In: Alimentary pharmacology & therapeutics, Vol. 34, no. 4, p. 432-42 (2011)
Permanent URL
  1. Longstreth George F., Thompson W. Grant, Chey William D., Houghton Lesley A., Mearin Fermin, Spiller Robin C., Functional Bowel Disorders, 10.1053/j.gastro.2005.11.061
  2. Camilleri M., Heading R. C., Thompson W. G., Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome, 10.1046/j.1365-2036.2002.01305.x
  3. Dorn Spencer D., Morris Carolyn B., Hu Yuming, Toner Brenda B., Diamant Nicholas, Whitehead William E., Bangdiwala Shrikant I., Drossman Douglas A., Irritable Bowel Syndrome Subtypes Defined by Rome II and Rome III Criteria are Similar : , 10.1097/mcg.0b013e31815bd749
  4. Hungin A. P. S., Whorwell P. J., Tack J., Mearin F., The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects, 10.1046/j.1365-2036.2003.01456.x
  5. Drossman Douglas A., Camilleri Michael, Mayer Emeran A., Whitehead William E., AGA technical review on irritable bowel syndrome, 10.1053/gast.2002.37095
  6. Kanazawa Motoyori, Palsson Olafur S., Thiwan Syed I.M., Turner Marsha J., van Tilburg Miranda A.L., Gangarosa Lisa M., Chitkara Denesh K., Fukudo Shin, Drossman Douglas A., Whitehead William E., Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits, 10.1111/j.1572-0241.2008.02066.x
  7. Ford, BMJ, 13, 337 (2008)
  8. Lesbros-Pantoflickova D., Michetti P., Fried M., Beglinger C., Blum A. L., Meta-analysis: the treatment of irritable bowel syndrome, 10.1111/j.1365-2036.2004.02267.x
  9. Battaglia, Morselli-Labate, Camarri, Francavilla, Marco, Mastropaolo, Naccarato, Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study, 10.1046/j.1365-2036.1998.00397.x
  10. Poynard T., Regimbeau C., Benhamou Y., Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, 10.1046/j.1365-2036.2001.00937.x
  11. Gallego D., Aulí M., Aleu J., Martínez E., Rofes L., Martí-ragué J., Jiménez M., Clavé P., Effect of otilonium bromide on contractile patterns in the human sigmoid colon : Otilonium bromide inhibits human sigmoid motility, 10.1111/j.1365-2982.2010.01495.x
  12. Czimmer József, Sütő Gábor, Király Agnes, Mózsik Gyula, Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome, 10.1016/s0928-4257(01)00020-1
  13. TACK J., FRIED M., HOUGHTON L. A., SPICAK J., FISHER G., Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective, 10.1111/j.1365-2036.2006.02938.x
  14. Committee for Proprietary Medicinal Products (CPMP) Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome
  15. Patrick Donald L., Drossman Douglas A., Frederick Ihunnaya O., Dicesare Joseph, Puder Katherine L., 10.1023/a:1018831127942
  16. Glende Manfred, Morselli-Labate Antonio M, Battaglia Giuseppe, Evangelista Stefano, Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome : , 10.1097/00042737-200212000-00008
  17. Strege P. R., Sha L., Beyder A., Bernard C. E., Perez-Reyes E., Evangelista S., Gibbons S. J., Szurszewski J. H., Farrugia G., T-type Ca2+ channel modulation by otilonium bromide, 10.1152/ajpgi.00437.2009
  18. Evangelista, J Int Med Res, 27, 207 (1999)
  19. Evangelista, Drug Metab Dispos, 28, 643 (2000)
  20. Posserud Iris, Syrous Alma, Lindström Lina, Tack Jan, Abrahamsson Hasse, Simrén Magnus, Altered Rectal Perception in Irritable Bowel Syndrome Is Associated With Symptom Severity, 10.1053/j.gastro.2007.07.024
  21. Sutton J. A., Kilminster S. G., Mould G. P., The clinical phcarmacology of single doses of otilonium bromide in healthy volunteers, 10.1007/s002280050302
  22. Narducci Francesco, Bassotti Gabrio, Granata Maria Teresa, Pelli Maria Antonia, Gaburri Manuela, Palumbo Renato, Morelli Antonio, Colonic motility and gastric emptying in patients with irritable bowel syndrome effect of pretreatment with octylonium bromide, 10.1007/bf01318114
  23. Musial Frauke, Placebo responses in patients with gastrointestinal disorders, 10.3748/wjg.v13.i25.3425
  24. Price Donald D., Craggs Jason, Nicholas Verne G., Perlstein William M., Robinson Michael E., Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients : , 10.1016/j.pain.2006.08.001